Minodronic acid (BioDeep_00000015350)

Main id: BioDeep_00000180965

 


代谢物信息卡片


Minodronic acid

化学式: C9H12N2O7P2 (322.0119742)
中文名称: 米诺膦酸
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
InChI: InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)

描述信息

C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor
D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].

同义名列表

2 个代谢物同义名

Minodronic acid; YM-529



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Takuya Morinishi, Aya Nawata, Ryo Konishi, Erina Ono, Koji Takaori, Sayako Maeda. Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate. CEN case reports. 2022 02; 11(1):120-125. doi: 10.1007/s13730-021-00637-3. [PMID: 34455572]
  • Masaki Kobayashi, Kenjiro Sawada, Akihiko Yoshimura, Misa Yamamoto, Aasa Shimizu, Kotaro Shimura, Naoko Komura, Mayuko Miyamoto, Kyoso Ishida, Tadashi Kimura. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study. BMC women's health. 2020 03; 20(1):48. doi: 10.1186/s12905-020-00913-x. [PMID: 32138724]
  • Yukari Uemura, Shiro Tanaka, Teruhiko Miyazaki, Mayumi Tsukiyama, Teruki Sone, Akira Taguchi, Satoshi Soen, Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Masao Fukunaga, Hiroaki Ohta, Toshitaka Nakamura, Hajime Orimo, Masataka Shiraki. Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Journal of bone and mineral metabolism. 2019 May; 37(3):491-495. doi: 10.1007/s00774-018-0942-z. [PMID: 30019249]
  • Tsuyoshi Ohishi, Tomotada Fujita, Daisuke Suzuki, Tatsuya Nishida, Mitsuru Asukai, Yukihiro Matsuyama. Serum homocysteine levels are affected by renal function during a 3-year period of minodronate therapy in female osteoporotic patients. Journal of bone and mineral metabolism. 2019 Mar; 37(2):319-326. doi: 10.1007/s00774-018-0920-5. [PMID: 29603071]
  • Hironori Tanabe, Yoichi Aota, Yasuteru Yamaguchi, Kanichiro Kaneko, Sousuke Imai, Masaki Takahashi, Masataka Taguri, Tomoyuki Saito. Minodronate treatment improves low bone mass and reduces progressive thoracic scoliosis in a mouse model of adolescent idiopathic scoliosis. PloS one. 2018; 13(8):e0202165. doi: 10.1371/journal.pone.0202165. [PMID: 30138335]
  • Tsuyoshi Ohishi, Tomotada Fujita, Daisuke Suzuki, Tatsuya Nishida, Kazufumi Yamamoto, Ryo Okabayashi, Hiroki Ushirozako, Tomohiro Banno, Yukihiro Matsuyama. Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients. Endocrine research. 2017 Aug; 42(3):232-240. doi: 10.1080/07435800.2017.1292527. [PMID: 28318330]
  • Kazuki Fujimoto, Kazuhide Inage, Sumihisa Orita, Masaomi Yamashita, Koki Abe, Masatsune Yamagata, Takeshi Sainoh, Tsutomu Akazawa, Tomoaki Kinoshita, Tetsuharu Nemoto, Jiro Hirayama, Yasuaki Murata, Toshiaki Kotani, Yasuchika Aoki, Yawara Eguchi, Takeshi Sakuma, Takahito Aihara, Tetsuhiro Ishikawa, Kaoru Suseki, Eiji Hanaoka, Kazuyo Yamauchi, Gou Kubota, Miyako Suzuki, Jun Sato, Yasuhiro Shiga, Hirohito Kanamoto, Masahiro Inoue, Hideyuki Kinoshita, Masao Koda, Takeo Furuya, Kazuhisa Takahashi, Seiji Ohtori. The nature of osteoporotic low back pain without acute vertebral fracture: A prospective multicenter study on the analgesic effect of monthly minodronic acid hydrate. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2017 Jul; 22(4):613-617. doi: 10.1016/j.jos.2017.01.022. [PMID: 28284540]
  • Kosuke Ebina, Takaaki Noguchi, Makoto Hirao, Shoichi Kaneshiro, Yasunori Tsukamoto, Hideki Yoshikawa. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis. Journal of bone and mineral metabolism. 2016 May; 34(3):243-50. doi: 10.1007/s00774-015-0710-2. [PMID: 26303222]
  • Atsushi Imai, Kazutoshi Matsunami, Satoshi Ichigo, Hiroshi Takagi. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2016; 32(3):250-2. doi: 10.3109/09513590.2015.1112783. [PMID: 26503621]
  • Yong Yang, Cai Liu, Yifan Zhang, Lei Zhou, Dafang Zhong, Xiaoyan Chen. On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method. Journal of pharmaceutical and biomedical analysis. 2015 Oct; 114(?):408-15. doi: 10.1016/j.jpba.2015.05.038. [PMID: 26117452]
  • Jun Iwamoto, Tetsuya Takada. Effect of minodronate on the speed of sound of the calcaneus in postmenopausal women with an increased risk of fractures: A clinical practice-based observational study. Journal of the Chinese Medical Association : JCMA. 2015 Oct; 78(10):591-6. doi: 10.1016/j.jcma.2015.06.010. [PMID: 26231577]
  • Atsushi Kurabayashi, Keiji Inoue, Hideo Fukuhara, Takashi Karashima, Satoshi Fukata, Chiaki Kawada, Taro Shuin, Mutsuo Furihata. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma. Cancer science. 2015 Aug; 106(8):1092-9. doi: 10.1111/cas.12711. [PMID: 26041278]
  • Ying Zhou, Xiaomeng He, Huqun Li, Yang Ni, Mingzhen Xu, Haseeb Sattar, Hui Chen, Weiyong Li. Pharmacokinetics and tolerability of minodronic acid tablets in healthy Chinese subjects and food and age effects on the pharmacokinetics. Clinical therapeutics. 2015 Apr; 37(4):869-76. doi: 10.1016/j.clinthera.2015.01.015. [PMID: 25748293]
  • A Sakai, S Ikeda, N Okimoto, H Matsumoto, K Teshima, Y Okazaki, F Fukuda, S Arita, H Tsurukami, M Nagashima, T Yoshioka. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2014 Sep; 25(9):2245-53. doi: 10.1007/s00198-014-2756-8. [PMID: 24899103]
  • Aishi Kimoto, Makoto Tanaka, Kazutoshi Nozaki, Masamichi Mori, Shinji Fukushima, Hiroshi Mori, Tsutomu Shiroya, Toshitaka Nakamura. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment. Bone. 2013 Jul; 55(1):189-97. doi: 10.1016/j.bone.2013.02.013. [PMID: 23486179]
  • Toru Yoshioka, Nobukazu Okimoto, Ken Okamoto, Akinori Sakai. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients. Journal of bone and mineral metabolism. 2013 Mar; 31(2):153-60. doi: 10.1007/s00774-012-0393-x. [PMID: 23076293]
  • Takanori Komada, Yoshiyuki Morishita, Masafumi Kitamura, Kana Iwazu, Akihiko Numata, Takahisa Kobayashi, Hisashi Yamamoto, Tetsu Akimoto, Osamu Saito, Yasuhiro Ando, Fumi Takemoto, Shigeaki Muto, Wako Yumura, Eiji Kusano. Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate). Internal medicine (Tokyo, Japan). 2013; 52(12):1383-7. doi: 10.2169/internalmedicine.52.0094. [PMID: 23774552]
  • Shinji Tanishima, Yasuo Morio. A review of minodronic acid hydrate for the treatment of osteoporosis. Clinical interventions in aging. 2013; 8(?):185-9. doi: 10.2147/cia.s23927. [PMID: 23440003]
  • R Okazaki, H Hagino, M Ito, T Sone, T Nakamura, H Mizunuma, M Fukunaga, M Shiraki, Y Nishizawa, Y Ohashi, T Matsumoto. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Jun; 23(6):1737-45. doi: 10.1007/s00198-011-1782-z. [PMID: 21932114]
  • K Amagase, A Inaba, T Senta, Y Ishikawa, K Nukui, T Murakami, Koji Takeuchi. Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2011 Dec; 62(6):609-18. doi: . [PMID: 22314563]
  • Masako Ito, Teruki Sone, Masao Fukunaga. Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. Journal of bone and mineral metabolism. 2010 May; 28(3):334-41. doi: 10.1007/s00774-009-0138-7. [PMID: 19937358]
  • Hiroshi Hagino, Yoshiki Nishizawa, Teruki Sone, Hirotoshi Morii, Yuji Taketani, Toshitaka Nakamura, Akira Itabashi, Hideaki Mizunuma, Yasuo Ohashi, Masataka Shiraki, Toshiomi Minamide, Toshio Matsumoto. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009 Jun; 44(6):1078-84. doi: 10.1016/j.bone.2009.02.016. [PMID: 19264155]
  • Masao Fukunaga. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis]. Clinical calcium. 2009 Jan; 19(1):63-73. doi: clica09016373. [PMID: 19122266]
  • Makoto Tanaka, Hiroshi Mori, Ryoji Kayasuga, Yasuo Ochi, Naoki Kawada, Hiroyuki Yamada, Katsuya Kishikawa. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone. 2008 Nov; 43(5):894-900. doi: 10.1016/j.bone.2008.07.002. [PMID: 18687415]
  • Hiroshi Mori, Makoto Tanaka, Ryoji Kayasuga, Taisei Masuda, Yasuo Ochi, Hiroyuki Yamada, Katsuya Kishikawa, Masako Ito, Toshitaka Nakamura. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone. 2008 Nov; 43(5):840-8. doi: 10.1016/j.bone.2008.07.242. [PMID: 18718565]
  • Takeshi Yuasa, Masaki Nogawa, Shinya Kimura, Asumi Yokota, Kiyoshi Sato, Hidekazu Segawa, Junya Kuroda, Taira Maekawa. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Jan; 11(2 Pt 1):853-9. doi: . [PMID: 15701876]
  • Seiji Yano, Helong Zhang, Masaki Hanibuchi, Toyokazu Miki, Hisatsugu Goto, Hisanori Uehara, Saburo Sone. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Nov; 9(14):5380-5. doi: NULL. [PMID: 14614023]
  • Helong Zhang, Seiji Yano, Toyokazu Miki, Hisatsugu Goto, Takanori Kanematsu, Hiroaki Muguruma, Hisanori Uehara, Saburo Sone. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Clinical & experimental metastasis. 2003; 20(2):153-9. doi: 10.1023/a:1022621622063. [PMID: 12705636]
  • T Michigami, H Yamato, H Suzuki, Y Nagai-Itagaki, K Sato, K Ozono. Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy. The Journal of endocrinology. 2001 Nov; 171(2):249-57. doi: 10.1677/joe.0.1710249. [PMID: 11691644]
  • S Ohmori, K Kurokouchi, K Kanda, S Kawano, T Ito, M Inazu, F Kambe, H Seo. Changes in urinary excretion of deoxypyridinoline in tail-suspended rats: effects of a bisphosphonate, YH529. Environmental medicine : annual report of the Research Institute of Environmental Medicine, Nagoya University. 1998 Oct; 42(1):11-3. doi: NULL. [PMID: 12212616]
  • Y Yoshida, A Moriya, K Kitamura, M Inazu, N Okimoto, Y Okazaki, T Nakamura. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1998 Jun; 13(6):1011-22. doi: 10.1359/jbmr.1998.13.6.1011. [PMID: 9626633]
  • S Ohmori, K Kurokouchi, K Kanda, S Kawano, T Ito, R Izumi, K Yasukawa, M Inazu, Y Murata, H Seo. Effect of bisphosphonate administration on the excretion of stress hormones in tail-suspended rats. Environmental medicine : annual report of the Research Institute of Environmental Medicine, Nagoya University. 1997 Oct; 41(1):9-12. doi: NULL. [PMID: 12523372]
  • T Usui, R Kawakami, T Watanabe, S Higuchi. Sensitive determination of a novel bisphosphonate, YM529, in plasma, urine and bone by high-performance liquid chromatography with fluorescence detection. Journal of chromatography. 1994 Jan; 652(1):67-72. doi: 10.1016/0378-4347(93)e0397-9. [PMID: 8014229]